Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA ("Oncoinvent" or the "Company") 31 October 2025 regarding the appointment of Ramzi Amri as the new CEO of the Company as of January 2026. The Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 0.4671, equal to the volume weighted average share price the last day before the grant. Following the grant of the 5,430,000 share options referred to above, Ramzi Amri hold no shares and 5,430,000 options in the Company.

Each option, when exercised, will give the right to acquire one share in the Company. The options are granted without consideration. Pursuant to the vesting schedule, 25% of the options will vest 12 months after the day of grant (as long as the option holder is still employed). Thereafter, 1/36 of the remaining options will vest each month as long as the option holder is still employed, with the first 1/36 vesting 13 months after the day of grant. Options that have not been exercised will lapse 7 years after the date of grant.

The number of options and strike price in this grant will be adjusted when the reverse share split approved in the Extraordinary General Meeting 8 January 2026 is effective.

The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers. 

PDMR notification Ramzi Amri

This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act.